Akari Therapeutics, Plc Employee Directory
Biotechnology ResearchEngland, United Kingdom11-50 Employees
Akari Therapeutics, Plc is a London, England–based biotechnology company focused on oncology. It develops antibody-drug conjugates that use a novel RNA splicing modulator payload called PH1, which disrupts RNA splicing in cancer cells and offers a mechanism distinct from traditional ADC payloads. In preclinical models, PH1 has been associated with cancer cell death and immune activation, supporting the potential to generate multiple ADCs for different targets. The lead candidate AKTX-101 targets the Trop2 receptor and delivers PH1 into tumors, with preclinical studies showing significant activity and prolonged survival relative to ADCs with traditional payloads. In 2026, Akari announced collaborations, including a development and manufacturing partnership with WuXi XDC, reflecting ongoing external partnerships as the company validates PH1 and pursues additional targets.
1-888-653-2347 
support@leadiq.com 
